Æterna Zentaris Inc.Find Ratings Reports
AETERNA ZENTARIS INC's gross profit margin for the first quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. AETERNA ZENTARIS INC is extremely liquid. Currently, the Quick Ratio is 3.09 which clearly shows the ability to cover any short-term cash needs. AEZS managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 147.38% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY20||Q1 FY19|
|Net Sales ($mil)||1.09||0.04|
|Net Income ($mil)||0.78||-4.91|
|Balance Sheet||Q1 FY20||Q1 FY19|
|Cash & Equiv. ($mil)||9.18||11.36|
|Total Assets ($mil)||19.64||22.38|
|Total Debt ($mil)||0.36||1.76|
|Profitability||Q1 FY20||Q1 FY19|
|Gross Profit Margin||30.73||-6394.59|
|Return on Assets||-1.79||-67.67|
|Return on Equity||-20.86||0.0|
|Debt||Q1 FY20||Q1 FY19|
|Share Data||Q1 FY20||Q1 FY19|
|Shares outstanding (mil)||23.47||16.44|
|Div / share||0.0||0.0|
|Book value / share||0.07||-0.22|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||385604.0||287123.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 12.67 indicates a significant premium versus the S&P 500 average of 3.29 and a significant premium versus the subsector average of 9.94. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, AETERNA ZENTARIS INC proves to trade at a premium to investment alternatives.
|AEZS NM||Peers 34.42||AEZS NM||Peers 44.62|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AEZS's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AEZS's P/CF is negative making the measure meaningless.
|AEZS NA||Peers 34.32||AEZS NA||Peers 0.81|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AEZS 12.67||Peers 9.94||AEZS 97.83||Peers 7.49|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AEZS is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AEZS is expected to have an earnings growth rate that significantly exceeds its peers.
|AEZS 13.43||Peers 507.84||AEZS -29.87||Peers 147.73|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AEZS is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
AEZS significantly trails its peers on the basis of sales growth.